Thomas J. Digby, Attorney

Global IP

                Asset Management

ABOUT

Tom is a US/Canadian intellectual property (IP) and transaction attorney with 22+ years’ experience in Global IP Asset Management

TECHNOLOGY

  • Small molecule NCEs

  • Biologics

  • Generics and biosimilars

  • Research tools and therapeutic targets

  • Biofuel and biomass derived chemicals

EXPERIENCE

  • 12+ years in seed stage biotech and cleantech

  • 10+ years in global pharma (Novartis)

CLIENTS

  • VC funds seeking in-depth, versatile and fast results

  • Start-up biotechs with complex early stage IP portfolios

 

...Tom cuts through minutiae to distill to pragmatic matters important for a business investment decision, allowing us to distinguish those IP-related issues which can be resolved versus the issues that are investment no-goes.

Managing Director, Corporate VC

US AND CANADIAN REGISTRATIONS

State Bar Registration (US)

Bar Admission (Canada)

  • New York, 1995

  • Massachusetts, 1995

  • Ontario (Canada), 1994

  • British Columbia (Canada), 1998

  • US Patent and Trademark Office, 2005-2012

     

Education

Professional Associations

  • Juris Doctor (J.D.)

       Dalhousie University, 1992

  • Master of Science (Biochemistry)

       Dalhousie University, 1990

  • Bachelor of Science (Honours) Queen's University, 1987

  • Licensing Executive Society (USA/Canada)

  • IP Institute of Canada

  • Life Sciences British Columbia

  • World Biofuel Association

  • Canadian Bar Association

  * Insured All Jurisdictions

 

AREAS OF PRACTICE

  • Securing patents, protecting know-how

  • Freedom-to-operate analysis

IP due diligence, agreements and negotiations for:

  • Licensing

  • M&A

  • Financing (Equity and debt)

  • Patent avoidance/Design-around strategy

  • Multi-country IP litigation assessment

  • International trade sanctions (IP aspects)

  • Multi-country IP licensing strategy

  • Regulatory data protection for pharmaceuticals and chemicals

  • IP enforcement strategy

  • Comparative analysis of national IP systems and policies

  • Pharmaceutical life-cycle management/Generic entry planning

  • Non-practicing entity (NPE or “patent troll”) defence and strategy

  • Royalty-rate comparables for license agreements and damage/settlement calculations

Global tax and transfer-pricing (IP aspects)

  • Global structure for beneficial/legal/registered ownership of IP assets

  • Global structure for internal supply chain licensing of IP assets

  • Litigation support regarding IP ownership in transfer-pricing arrangements

  • Dispute resolution (mediation, arbitration, litigation) for technology agreements

  • Portfolio cost savings and optimization

 
 

GLOBAL IP THOUGHT LEADERSHIP

For the latest on Pharma/Biotech, Global Trade and IP law in US, China and worldwide:

price short.jpeg
images.jpeg
Drugs.jpg
 

CONTACT

Thomas J. Digby

+1-604-362-9019

TJD@DigbyGlobal.com

Vancouver, Canada 

(Pacific time zone)

Free and confidential initial discussion

                      -

© Thomas J. Digby 2017